learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
5 / 12 resultslearn Fluridil
a topical anti-androgen with less systemic involvement
learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Bicalutamide
a nonsteroidal anti-androgen, most commonly used orally for women
Research
5 / 1000+ results
research 52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia
AH-001 could be a safer and more effective treatment for hair loss.
research Novel Androgen Receptor Degrader for Androgenetic Alopecia (AGA) Application
A new treatment for hair loss shows promise with fewer side effects.
research Novel Androgen Receptor Degrader for Androgenetic Alopecia Application
research Androgen Receptor Modulators: A Review of Recent Patents and Reports (2012-2018)
New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
Community Join
5 / 1000+ resultscommunity Androgen degraders for hair loss
The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community About GT20029's Efficacy and Strength
The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.
community Kintor’s GT20029 Phase 1 success
Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.
community Is Pyrilutamide the real deal and if so when will it actually be available?
Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.